0000000000026466

AUTHOR

Miguel Martín

POLYNOMIAL NUMERICAL INDEX FOR SOME COMPLEX VECTOR-VALUED FUNCTION SPACES

We study in this paper the relation between the polynomial numerical indices of a complex vector-valued function space and the ones of its range space. It is proved that the spaces C(K,X), and L∞(μ,X) have the same polynomial numerical index as the complex Banach space X for every compact Hausdorff space K and every σ-finite measure μ, which does not hold any more in the real case. We give an example of a complex Banach space X such that, for every k > 2, the polynomial numerical index of order k of X is the greatest possible, namely 1, while the one of X∗∗ is the least possible, namely k k 1−k . We also give new examples of Banach spaces with the polynomial Daugavet property, namely L∞(μ,X…

research product

Abstract LB061: On-target peripheral and tumor immune microenvironment modulation in patients treated with lacnotuzumab (anti-CSF1, MCS110) + spartalizumab

Abstract Background: The CSF-1/CSF-1R (colony-stimulating factor-1) pathway plays a significant role in the tumor microenvironment via regulation of tumor-associated macrophages (TAMs). Lacnotuzumab (MCS110) is a humanized monoclonal antibody against CSF-1. Lacnotuzumab may counteract the tumor suppressive microenvironment induced by CSF-1, potentially enhancing the efficacy of PD-1 inhibition. Methods: MCS110Z2102 is a phase 1b/2 study in cancer patients with advanced malignancies treated by lacnotuzumab combined with the PD-1 inhibitor spartalizumab. Eligible patients with previously treated advanced/metastatic solid tumors received 1, 3, 5, 7.5 and 10 mg/kg intravenous doses of lacnotuzu…

research product

Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial.

2606 Background: Balixafortide (B) is a potent antagonist of the chemokine receptor CXCR4. Preclinical evidence suggests that disrupting CXCR4 dependent pathways prevents development of breast cancer metastases, enhances the cytotoxic effect of chemotherapy and immunotherapy, and counteracts tumor cell evasion of the immune system. Encouraging safety and efficacy data were published recently from the ongoing Phase 1 trial investigating B + eribulin (E) in patients with HER2 negative MBC (Pernas S. et al. Lancet Oncol. 2018; 19: 812−24). The objective response rate, median progression free survival and median overall survival (OS) for the expanded cohort (EC) and the overall efficacy popula…

research product

The role of charophytes in a Mediterranean pond created forrestoration purposes

A small, shallow basin was created and flooded with groundwater in a Reserve Area in Albufera de València Natural Park (AVNP) under the scope of a restoration program intended to mimic typical environments such as freshwater springs, abundant in the past but currently suffering from deterioration (desiccation, pollution, etc.), with the ultimate goal of increasing local biodiversity of submerged macrophytes, particularly charophytes. In this study we have monitored, from April 2009 (a few months after its first flooding) to September 2012, the dynamics of charophyte growth and related physical, chemical and biotic variables to highlight the factors determining charophyte success. Just after…

research product

Dynamics, Operator Theory, and Infinite Holomorphy

research product

Fixed‐Bed Removal of Free and Complexed Ni from Synthetic and Industrial Aqueous Solutions

Abstract This paper evaluates the application of several biosorbents for Ni removal from aqueous solutions in the absence and in the presence of EDTA. Fixed bed experiments were performed (Ni influent concentration, 2 mg dm−3; EDTA doses, 0, 5, and 10 mg dm−3; pH=7) to study the process feasibility as refining after conventional physicochemical treatment. In absence of EDTA, uptake capacity followed the order peat > Posidonia oceanica > chitosan > chitin ≫ Scharlau AC. Maximum uptakes of 8.95 mg g−1 and 5.10 mg g−1 were found for peat and Posidonia oceanica, respectively. In the presence of EDTA, removal capacity decreased for all biosorbents; Ni was detected in the effluent from the beginn…

research product

Balixafortide (a CXCR4 antagonist) plus eribulin in HER2 negative metastatic breast cancer: Dose-response analysis of efficacy from phase I single-arm trial.

e15209 Background: Balixafortide (B) is a potent, selective antagonist of the chemokine receptor CXCR4. High CXCR4 levels correlate with aggressive metastatic phenotypes and poor prognosis in metastatic breast cancer (MBC). Efficacy and safety data were published recently from the Phase 1 trial investigating B + eribulin (E) in patients with HER2 negative MBC1. We report the final efficacy analyses from this trial, including assessment of dose-response. Methods: In this single-arm, dose escalation trial, patients (pts) received E + increasing doses of B using a 3+3 design in 3 parts: Part I (cohorts received low E doses); Part II (dose-escalation cohort for B [1−5.5mg/kg] + 1.4mg/m2 E); Ex…

research product

Removal of TEX vapours from air in a peat biofilter: influence of inlet concentration and inlet load

This paper presents the results of the study of the removal of toluene, ethylbenzene, and o-xylene (TEX) by biofiltration using a commercial peat as filter-bed material. Runs with a single organic compound in air, and with the mixture of TEX in air, were carried out for at least 55 days in laboratory-scale reactors inoculated with a conditioned culture. The influence of organic compound inlet load and of gas flow rate on the biofilter's performance was studied, including relatively high values of pollutant inlet concentration (up to 4.3 gC m−3 for ethylbenzene, 3.2 gC m−3 for toluene, and 2.7 gC m−3 for o-xylene). Results obtained show maximum elimination capacities of 65 gC m−3 h−1 for o-x…

research product

Recomendación para la determinación de HER2 en cáncer de mama. Consenso nacional de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM)

La identificación de los carcinomas de mama con amplificación/sobreexpresión de HER2 es crítica en la práctica clínica diaria ya que estas neoplasias requieren un tratamiento específico que incluye el uso de terapias dirigidas. Tanto las técnicas de hibridación in situ como las técnicas inmunohistoquímicas son métodos apropiados para la identificación de cánceres de mama HER2 positivos. Sin embargo, numerosos estudios, incluidos los desarrollados por la Asociación para la Garantía de Calidad en Patología de la SEAP (AGCP) y la experiencia de centros de referencia nacionales en la determinación de HER2 han puesto de manifiesto importantes problemas de reproducibilidad entre laboratorios. Por…

research product

Two-dimensional Banach spaces with polynomial numerical index zero

We study two-dimensional Banach spaces with polynomial numerical indices equal to zero.

research product

Performance of surface and subsurface flow constructed wetlands treating eutrophic waters

[EN] Three medium size constructed wetlands (CWs) with a total surface of 90 ha are working since 2009 in the Albufera de Valencia Natural Park (Spain). Two of them are fed with eutrophic waters from l'Albufera Lake. Their objectives are both reduce the phytoplankton biomass and increase the biodiversity; consequently, improved water quality is returned to the lake. A "science based governance" of these CWs is ongoing inside the LIFE + 12 Albufera Project to demonstrate the environmental benefits of these features. In this paper, results and relationships among hydraulic operation, physicochemical variables and plankton in two different CWs typologies, five free water surface CW (FWSCW) and…

research product

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

AbstractBackgroundNeoadjuvant treatment is increasingly one of the preferred therapeutic options for early breast cancer and may have some unique outcomes, such as identifying predictive and prognostic factors of response or increasing the knowledge of individual tumor biology.DesignA panel of experts from different specialties reviewed published clinical studies on the neoadjuvant management of breast cancer. Recommendations were made that emphasized the clinical multidisciplinary management and the investigational leverage in early breast cancer.ResultsNeoadjuvant therapy has equivalent efficacy to adjuvant therapy, and it has some additional benefits that include increasing breast conser…

research product

The role of eutrophication reduction of two small man-made Mediterranean lagoons in the context of a broader remediation system: Effects on water quality and plankton contribution

In order to meet the requirements of the European Union Water Framework Directive for the Albufera de Valencia (AV) Natural Park, in 2009, several areas of free water surface constructed wetlands (FWSCWs) planted with emergent vegetation and two small shallow lagoons planted with submerged macrophytes were created over a 40-ha area formerly occupied by rice fields. This area is currently a reserve known as Tancat de la Pipa. The dual goal of this programme was to improve the quality of the hyper-eutrophicated waters of the AV lagoon, the largest littoral lagoon in the Iberian Peninsula, and to restore former lost habitats to increase the biodiversity of the area. The lagoons were mainly fed…

research product

Polynomial numerical indices of 𝐶(𝐾) and 𝐿₁(𝜇)

We estimate the polynomial numerical indices of the spaces C ( K ) C(K) and L 1 ( μ ) L_1(\mu ) .

research product

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

Altres ajuts: Agustí Barnadas: Honoraria: Pfizer. Consulting or Advisory Role: Pfizer, Novartis, Eli Lilly. Speakers'Bureau: Roche, Pfizer, Novartis, Genomic Health International. Travel, Accommodations, Expenses: Roche, Pfizer; Miguel A. Seguí: Consulting or Advisory Role: Roche, Pfizer, Novartis, Amgen, Eisai, Eli Lilly. Speakers' Bureau: Roche, Pfizer, Amgen. Research Funding: Roche (Inst), Novartis (Inst). Travel, Accommodations, Expenses: Roche, Pfizer, Novartis, Amgen. Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion of sta…

research product

Biofiltration of ethylbenzene vapours: influence of the packing material.

In order to investigate suitable packing materials, a soil amendment composed of granular high mineralized peat (35% organic content) locally available has been evaluated as carrier material for biofiltration of volatile organic compounds in air by comparison with a fibrous peat (95% organic content). Both supports were tested to eliminate ethylbenzene from air streams in laboratory-scale reactors inoculated with a two-month conditioned culture. In pseudo-steady state operation, experiments at various ethylbenzene inlet loads (ILs) were carried out. Maximum elimination capacity of about 120 g m(-3) h(-1) for an IL of 135 g m(-3) h(-1) was obtained for the fibrous peat. The soil amendment re…

research product

The Daugavet equation for polynomials

In this paper we study when the Daugavet equation is satisfied for weakly compact polynomials on a Banach space X, i.e. when the equality ‖Id + P‖ = 1 + ‖P‖ is satisfied for all weakly compact polynomials P : X −→ X. We show that this is the case when X = C(K), the real or complex space of continuous functions on a compact space K without isolated points. We also study the alternative Daugavet equation max |ω|=1 ‖Id + ω P‖ = 1 + ‖P‖ for polynomials P : X −→ X. We show that this equation holds for every polynomial on the complex space X = C(K) (K arbitrary) with values in X. The result is not true in the real case. Finally, we study the Daugavet and the alternative Daugavet equations for k-h…

research product

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature

Abstract Background Trastuzumab emtansine (T-DM1), a new agent developed for the treatment of HER2-positive breast cancer, is an antibody-drug conjugate with a complex compound obtained by the conjugation of trastuzumab, a stable thioether linker, and the potent cytotoxic drug maytansine-derivate(DM1), which inhibits cell division and induces cell death. Field of study PubMed database, ESMO, ASCO, San Antonio Breast Cancer Symposium Meeting abstracts and clinicaltrials.gov were searched using the terms “Anti-HER2 treatment breast cancer and trastuzumab emtansine (T-DM1) “; papers considered relevant for the aim of this review were selected. Findings/results The phase I trials have determine…

research product

Breast cancer risk among women following lifestyle recommendations: A case-control study in Spain.

1602 Background: In 2007, the World Cancer Research Fund (WCRF) and the American Institute of Cancer Research (AICR) issued 8 general and 2 special recommendations for cancer prevention based on av...

research product